Posted by Michael Wonder on 06 Jan 2020
FDA approves Fiasp for treatment of children with diabetes
6 January 2020 - Novo Nordisk today announced that the U.S. FDA has approved Fiasp (insulin aspart injection) 100 u/mL for use as a new mealtime insulin option for children with diabetes.
Fiasp is the first and only fast-acting mealtime insulin injection that does not have a pre-meal dosing recommendation. Fiasp is now available for use in children and adults in three different dosing options: multiple daily injections, continuous subcutaneous insulin infusion pumps and intravenous infusion under supervision by a healthcare professional.
The approval is based on the FDA's review of data from the onset 7 clinical trial, which confirmed the efficacy and safety of Fiasp in children.
